Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases. Backed by 5AM Ventures.
About the role
This position will report to the Director of Business Development and Corporate Strategy and support a variety of projects for the early commercial strategy team. Example workstreams include partnership and ownership across competitive intelligence, market research, and forecasting analysis. You’ll conduct primary and secondary market research to gather data to drive key insights and analyses to support Entrada’s pre-commercial strategy. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Bachelor’s degree in a life sciences discipline required, PhD, MBA or other advanced degree strongly preferred
- 5+ years of relevant experience, preferably in an analytical role such as market research, equity research, life sciences consulting, commercial analytics, or prior experience in biotech/pharma
- Direct experience synthesizing and communicating competitive insights from drug development programs and/or companies
- Exceptional analytical skills combined with a broad understanding of the life sciences business and R&D process
- Excellent communication skills engaging with external experts and internal stakeholders to gather insights and feedback
- Experience building and interpreting financial models and communicating modeling outputs to support strategic decision making
More about this role
What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1).
2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex...
Browse similar: Startup jobs · Boston